Vatsal Patel, MD
Radiation Oncology · Las Vegas, NVNPI 1447696745
Payments from drug & device makers
What this record shows
AstraZeneca accounts for 62.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $525 and has fallen 69.4% since, to $161 in 2025. That places this record below the midpoint for radiation oncology clinicians in NV, where the typical reported total is $884.
Across 16 payments — averaging $55.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$557
- Incyte Corporation$118
- Sobi, Inc$29
- Seagen Inc.$25
- Stemline Therapeutics Inc.$24
- GSK$22
- plus $120 from 8 others
What the payments were for
- Consulting fees$52559%
- Food & beverage$37041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $557 |
| Incyte Corporation | 1 | $118 |
| Sobi, Inc | 1 | $29 |
| Seagen Inc. | 2 | $25 |
| Stemline Therapeutics Inc. | 1 | $24 |
| GSK | 1 | $22 |
| Boston Scientific | 1 | $20 |
| Bayer | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Blueprint Medicines Corporation | 1 | $13 |
| Ipsen Biopharmaceuticals, Inc | 1 | $11 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$895 in reported general payments places this provider in the 50th percentile of 47 radiation oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Las Vegas
- Farzaneh FarzinLas Vegas$12K
- Samual FrancisLas Vegas$10K
- Ritchie StevensLas Vegas$9K
- Anita PomerantzLas Vegas$9K
- Michael SinopoliLas Vegas$5K
- Andrew CohenLas Vegas$4K
- Raul MeozLas Vegas$3K
- Wei Gang WangLas Vegas$2K
- Robert O LaughlinLas Vegas$2K
- Robert BeckLas Vegas$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.